slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 71,611-71,640
Pages 3,683
Rows per page 30
Component
71,611-71,640 of 110,471
130
The slide uses a Q&A format to expose a fundamental flaw in the company's technology claims.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
134
The slide uses a red-circled chart to illustrate the 'sleight of hand' in data presentation.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
135
Includes expert commentary on technical limitations of multi-layer pouch cells.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Beat · Critique of Quantumscape's claims and technology1 hit
165
Uses a 'The Conversation' article as a diagnostic framework to critique the subject company.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
171
The slide uses a red arrow to connect a redacted excerpt from a lawsuit complaint directly to key takeaways about the fraud allegations.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
176
Uses a 'guilt by association' rhetorical strategy to cast doubt on the target company.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
01
This is a classic activist short-seller cover page, utilizing aggressive, emotionally charged language to frame the thesis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
08
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
09
The slide functions as a summary of the 'villain' or 'expose' narrative arc of the deck.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
12
Uses social media screenshots as primary evidence to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
18
The slide uses a Q&A format to build a case for the 'two-hit' hypothesis regarding drug interactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
19
The slide uses a combination of narrative description and citations of medical literature to establish the 'villain' (diazoxide) as dangerous.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
40
The slide uses a combination of narrative summary and direct Q&A transcript excerpts to build a case of potential clinical trial misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
42
The slide uses a Q&A format to highlight internal skepticism regarding clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
43
The slide uses a 'quote-highlight' structure to emphasize specific allegations of misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
46
The slide uses a causal chain argument to refute a competitor's (Soleno) mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
49
Uses a red-annotated chart to highlight the discrepancy between reported LBM and suspected fluid retention.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
50
Includes links to cached PDF documents as evidence of data discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
54
The slide emphasizes the credibility of the interviewees by linking them to specific published papers (C601 and C602).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
56
The slide uses direct quotes from an expert to highlight risks of cardiac events, seizures, and trial design flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
58
This slide functions as a 'villain_critique' or 'expose_contradiction' regarding the drug's clinical reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
62
The slide uses a 'nominee_bio' structure to present a 'villain_critique' or 'expose_contradiction' narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
67
The slide presents critical expert feedback on drug formulation and safety protocols.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
04
This slide functions as a legal/regulatory petition argument, using evidence-based reasoning to refute the adequacy of current safety warnings.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit